secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0000950170-25-089981
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health amends Statera license; may pay royalties in securities, directs up to $5.6M to Avenue Capital
--------------------------------------------------------------------------------

- Amended license agreement gives Tivic discretion to pay future royalties in cash or its own securities.
- Subsequent payments to Statera, up to $5.6M aggregate, will be paid directly to Avenue Capital on Statera's behalf.
- Original exclusive license for Entolimod (TLR5 agonist) for Acute Radiation Syndrome and option for other indications unchanged.
- License fee of $300K cash plus 945,785 common shares and convertible preferred shares already paid at closing in Feb 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025089981/0000950170-25-089981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025089981/tivc-20250618.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-089981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer